Перейти к содержанию

Royalty Pharma plc (RPRX) stock: revenue, earnings & dividend

Royalty Pharma plc (RPRX, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener RPRX · Nasdaq Pharma & Biotech US-NY

Key figures

Fiscal year
2025
Revenue
2.38 bn $
Revenue growth
5.1 %
Revenue growth 5y (p.a.)
2.3 %
Net income
771 m $
Net margin
32.4 %
Operating margin
65.6 %
Earnings per share (diluted)
1.78 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
19.6 bn $
Equity
9.71 bn $
Equity ratio
49.5 %
Return on equity
7.9 %
Cash
619 m $
Operating cash flow
2.49 bn $
Free cash flow
–
Shares outstanding
–

History

Revenue by fiscal year

2018 1.79 bn $
2019 1.81 bn $
2020 2.12 bn $
2021 2.29 bn $
2022 2.24 bn $
2023 2.35 bn $
2024 2.26 bn $
2025 2.38 bn $

Net income by fiscal year

2018 1.38 bn $
2019 2.35 bn $
2020 975 m $
2021 620 m $
2022 42.8 m $
2023 1.13 bn $
2024 859 m $
2025 771 m $

Dividend per share

2020 0.30 $
2021 0.68 $
2022 0.76 $
2023 0.80 $
2024 0.84 $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20252.38 bn $771 m $1.78 $–2.49 bn $
20242.26 bn $859 m $1.91 $0.84 $2.77 bn $
20232.35 bn $1.13 bn $2.53 $0.80 $2.99 bn $
20222.24 bn $42.8 m $0.10 $0.76 $2.14 bn $
20212.29 bn $620 m $1.49 $0.68 $2.02 bn $
20202.12 bn $975 m $1.32 $0.30 $2.03 bn $
20191.81 bn $2.35 bn $––1.67 bn $
20181.79 bn $1.38 bn $––1.62 bn $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)